Market Cap (In USD)
350.31 Million
Revenue (In USD)
1.93 Million
Net Income (In USD)
-62.59 Million
Avg. Volume
2.35 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.24-0.86
- PE
- -
- EPS
- -
- Beta Value
- -0.556
- ISIN
- US66737P6007
- CUSIP
- 66737P600
- CIK
- 1072379
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Linda F. Powers J.D.
- Employee Count
- -
- Website
- https://www.nwbio.com
- Ipo Date
- 2001-12-14
- Details
- Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
More Stocks
-
002942
-
MYCRMycronic AB (publ)
MYCR
-
0HI3
-
FF
-
ACRDFAcreage Holdings, Inc.
ACRDF
-
1816CGN Power Co., Ltd.
1816
-
IMTXImmatics N.V.
IMTX
-
GEKTERNA